43 studies found for:    "Insulinoma"
Show Display Options
Rank Status Study
1 Completed Laparoscopy to Remove Pancreatic Tumors (Insulinomas)
Condition: Insulinoma
Intervention: Procedure: Intraoperative ultrasound
2 Active, not recruiting EUS-guided Ethanol Ablation of an Insulinoma
Condition: Insulinoma
Intervention: Procedure: EUS-guided ethanol ablation
3 Recruiting 68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis
Conditions: Insulinoma;   Nesidioblastosis
Intervention: Drug: 68Ga-NOTA-exendin-4
4 Completed Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients
Conditions: Hyperinsulinism;   Hypoglycemia;   Insulinoma
Intervention: Other: 111In-exendin-4 imaging
5 Active, not recruiting
Has Results
Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
Conditions: Gastrin-Producing Neuroendocrine Tumor;   Malignant Pancreatic Gastrinoma;   Malignant Pancreatic Glucagonoma;   Malignant Pancreatic Insulinoma;   Malignant Pancreatic Somatostatinoma;   Pancreatic Alpha Cell Adenoma;   Pancreatic Beta Cell Adenoma;   Pancreatic Delta Cell Adenoma;   Pancreatic G-Cell Adenoma;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Pancreatic Carcinoma;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Biological: Bevacizumab;   Drug: Everolimus;   Drug: Octreotide Acetate
6 Recruiting Diagnosing and Treating Low Blood Sugar Levels
Conditions: Hypoglycemia;   Insulinoma
Intervention:
7 Active, not recruiting Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
Conditions: Adult Hepatocellular Carcinoma;   Advanced Adult Hepatocellular Carcinoma;   Endometrial Serous Adenocarcinoma;   Localized Non-Resectable Adult Liver Carcinoma;   Lung Carcinoid Tumor;   Malignant Pancreatic Gastrinoma;   Malignant Pancreatic Glucagonoma;   Malignant Pancreatic Insulinoma;   Malignant Pancreatic Somatostatinoma;   Metastatic Digestive System Neuroendocrine Tumor G1;   Ovarian Carcinosarcoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Surface Papillary Adenocarcinoma;   Pancreatic Alpha Cell Adenoma;   Pancreatic Beta Cell Adenoma;   Pancreatic Delta Cell Adenoma;   Pancreatic G-Cell Adenoma;   Pancreatic Polypeptide Tumor;   Recurrent Adult Liver Carcinoma;   Recurrent Digestive System Neuroendocrine Tumor G1;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Regional Digestive System Neuroendocrine Tumor G1;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IIIC Uterine Corpus Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer;   Uterine Carcinosarcoma
Interventions: Biological: Bevacizumab;   Drug: Temsirolimus
8 Recruiting New Imaging Procedure for the Localisation of Insulinoma and Transplanted Islet Cells
Conditions: Endogenous Hyperinsulinaemic Hypoglycaemia;   Transplanted Islet Cells
Intervention: Other: Ga -exendin PET/CT, In- exendin SPECT/CT, MRI
9 Available 18F-FDOPA PET in Neuroendocrine Tumours
Conditions: Thyroid Cancer, Medullary;   Carcinoid Tumor;   Pheochromocytoma;   Paraganglioma;   Insulinoma;   Neuroblastoma
Intervention: Drug: [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
10 Terminated Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   Gastrinoma;   Glucagonoma;   HER2-negative Breast Cancer;   Insulinoma;   Mucositis;   Oral Complications;   Pancreatic Polypeptide Tumor;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Recurrent Islet Cell Carcinoma;   Recurrent Renal Cell Cancer;   Somatostatinoma;   Stage III Renal Cell Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Renal Cell Cancer
Intervention: Drug: everolimus
11 Not yet recruiting Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Pancreatic Polypeptide Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: regorafenib;   Other: laboratory biomarker analysis
12 Withdrawn Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: dovitinib lactate;   Other: pharmacological study;   Other: laboratory biomarker analysis
13 Recruiting Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Liver Metastases;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: everolimus;   Other: placebo;   Other: laboratory biomarker analysis
14 Available 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia
Conditions: Congenital Hyperinsulinism;   Beckwith-Wiedemann Syndrome;   Insulinoma
Intervention: Drug: 18F-DOPA
15 Active, not recruiting Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Islet Cell Carcinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: temozolomide;   Drug: capecitabine;   Other: laboratory biomarker analysis
16 Active, not recruiting Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Pancreatic Cancer;   Somatostatinoma;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: capecitabine;   Drug: temozolomide;   Biological: bevacizumab
17 Active, not recruiting Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Pheochromocytoma;   Pancreatic Polypeptide Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Melanoma;   Recurrent Neuroendocrine Carcinoma of the Skin;   Recurrent Non-small Cell Lung Cancer;   Recurrent Pheochromocytoma;   Recurrent Renal Cell Cancer;   Somatostatinoma;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Melanoma;   Stage IV Non-small Cell Lung Cancer;   Stage IV Renal Cell Cancer;   Thyroid Gland Medullary Carcinoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: everolimus;   Drug: vatalanib;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Procedure: ultrasound imaging
18 Completed
Has Results
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Neuroendocrine Tumor;   Pancreatic Polypeptide Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma;   WDHA Syndrome
Intervention: Drug: sorafenib tosylate
19 Terminated Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Pancreatic Polypeptide Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Regional Gastrointestinal Carcinoid Tumor;   Somatostatinoma
Interventions: Drug: romidepsin;   Other: laboratory biomarker analysis
20 Completed Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Pancreatic Polypeptide Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma;   WDHA Syndrome
Interventions: Drug: gefitinib;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years